No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 386.6x · 10Y median 111.2x · 70th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:48:00.354Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Relay Therapeutics, Inc. (RLAY) stock was $18.26 as of Oct 6, 2026, 1:45 PM EDT, down 5.83% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +251.7% · 3-year avg +29.5%/yr · 5-year avg -7.9%/yr
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.40
Revenue Est.
$1.62M
Last Quarter Results
EPS
$-0.41
vs Estimate
$-0.39
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RLAY | $4.00B | $18.26 | -5.83% | +251.71% | -7.92% | N/A | N/A |
| 2ABCL | $4.02B | $13.18 | -4.35% | +132.62% | -3.57% | N/A | vs RLAY |
| 3ICUI | $3.95B | $158.10 | -2.04% | +32.04% | -7.18% | +2.51% | vs RLAY |
| 4LIVN | $4.14B | $75.34 | -1.43% | +42.96% | -1.66% | +2.48% | vs RLAY |
| 5RGC | $3.76B | $7.58 | +4.70% | -57.49% | +67.94% | N/A | vs RLAY |
| 6EWTX | $4.25B | $39.54 | -1.88% | +156.35% | +16.95% | N/A | vs RLAY |
forward FY estimate
N/A
$350000.00
vs Estimate
$960000.00
Consensus Rating
Based on 12 analysts
Average Price Target
$27.58
+51.1% upside
Low
$20.00
Current
$18.26
High
$32.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.43 | $-0.40 | $-0.35 | 8 |
| Quarter ending Dec 2026 | $-0.42 | $-0.37 | $-0.31 | 7 |
| Quarter ending Mar 2027 | $-1.22 | $-0.40 | $0.09 | 2 |
| Quarter ending Jun 2027 | $-1.24 | $-0.40 | $0.09 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.71 | $-1.60 | $-1.47 | 9 |
| FY 2027 | $-1.75 | $-1.61 | $-1.46 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $630272.00 | $1.62M | $3.60M | 6 |
| Quarter ending Dec 2026 | $441248.00 | $7.10M | $18.39M | 6 |
| Quarter ending Mar 2027 | $48186.00 | $775000.00 | $2.01M | 3 |
| Quarter ending Jun 2027 | $48186.00 | $775000.00 | $2.01M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.52M | $11.16M | $20.79M | 9 |
| FY 2027 | $13.34M | $19.54M | $25.71M | 8 |
